Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004326 · ClinicalTrials.gov registry record
Hippocampal Complex Volume and Memory Dysfunction in Cushing's Syndrome
A clinical trial, sponsored by National Center for Research Resources (NCRR).
- Completed
- Registry status
- 12
- Enrollment target
NCT00004326: Completed study, sponsored by National Center for Research Resources (NCRR).
NCT00004326 is a clinical trial that has completed, run by National Center for Research Resources (NCRR). The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004326 has completed, sponsored by National Center for Research Resources (NCRR).
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
Study Summary
OBJECTIVES: I. Evaluate whether chronic hypercortisolemia is specifically toxic to hippocampal cells and causes structural reduction of hippocampal volume in patients with Cushing's syndrome. II. Determine whether reduced hippocampal volume is associated with specific memory dysfunction. III. Examine the relationships of adrenal androgen to hippocampal volume and memory dysfunction. IV. Examine the reversibility of hippocampal structural changes and cognitive dysfunction after cortisol levels are normalized.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 1994-08 |
What the finished NCT00004326 record still lists
NCT00004326 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00004326 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004326 about?
NCT00004326 is a clinical study titled "Hippocampal Complex Volume and Memory Dysfunction in Cushing's Syndrome". OBJECTIVES: I. Evaluate whether chronic hypercortisolemia is specifically toxic to hippocampal cells and causes structural reduction of hippocampal volume in patients with Cushing's syndrome. II. Determine whether reduced hippocampal volume is associated with specific memory dysfunction. III. Exam...
What is the current status of trial NCT00004326?
This trial is currently completed. The enrollment target is 12 participants. The study started on 1994-08.
Who is sponsoring clinical trial NCT00004326?
This trial is sponsored by National Center for Research Resources (NCRR), which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia